Suppr超能文献

组织工程与再生医学中的骨髓基质干细胞

Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine.

作者信息

Polymeri A, Giannobile W V, Kaigler D

机构信息

Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, Michigan, USA.

出版信息

Horm Metab Res. 2016 Nov;48(11):700-713. doi: 10.1055/s-0042-118458. Epub 2016 Nov 21.

Abstract

Bone marrow stromal stem cells (BMSCs) are adult multipotent cells, which have the potential to differentiate into cell types of mesodermal origin, namely osteocytes, adipocytes, and chondrocytes. Due to their accessibility and expansion potential, BMSCs have historically held therapeutic promise in tissue engineering and regenerative medicine applications. More recently, it has been demonstrated that not only can bone marrow stromal stem cells directly participate in tissue regeneration, but they also have the capacity to migrate to distant sites of tissue injury, where they can participate in tissue repair either directly through their differentiation or indirectly through paracrine mechanisms. Additionally, they can elicit various immunomodulatory signals, which can attenuate the inflammatory and immune responses. As such, bone marrow stromal stem cells have been explored clinically for treatment of a wide variety of different conditions including bone defects, graft-vs.-host disease, cardiovascular diseases, autoimmune diseases, diabetes, neurological diseases, and liver and kidney diseases. This review provides an overview of current clinical applications of bone marrow stromal stem cells and discusses their therapeutic properties, while also addressing limitations of their use. PubMed, Ovid, and Google Scholar online databases were searched using several keywords, including "stem cells", "tissue engineering", tissue regeneration" and "clinical trials". Additionally, Clinical trials.gov was used to locate completed clinical trials using bone marrow derived stem cells.

摘要

骨髓基质干细胞(BMSCs)是成体多能细胞,具有分化为中胚层来源细胞类型的潜力,即骨细胞、脂肪细胞和软骨细胞。由于其易于获取和扩增潜力,骨髓基质干细胞在组织工程和再生医学应用中一直具有治疗前景。最近的研究表明,骨髓基质干细胞不仅可以直接参与组织再生,还具有迁移到远处组织损伤部位的能力,在那里它们可以通过分化直接参与组织修复,或者通过旁分泌机制间接参与组织修复。此外,它们可以引发各种免疫调节信号,从而减弱炎症和免疫反应。因此,骨髓基质干细胞已在临床上用于探索治疗多种不同疾病,包括骨缺损、移植物抗宿主病、心血管疾病、自身免疫性疾病、糖尿病、神经疾病以及肝脏和肾脏疾病。本综述概述了骨髓基质干细胞的当前临床应用,并讨论了它们的治疗特性,同时也探讨了其使用的局限性。使用了几个关键词在PubMed、Ovid和谷歌学术在线数据库中进行搜索,包括“干细胞”、“组织工程”、“组织再生”和“临床试验”。此外,Clinicaltrials.gov用于查找使用骨髓来源干细胞的已完成临床试验。

相似文献

1
Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine.
Horm Metab Res. 2016 Nov;48(11):700-713. doi: 10.1055/s-0042-118458. Epub 2016 Nov 21.
2
Clinical applications of mesenchymal stem cells.
Korean J Intern Med. 2013 Jul;28(4):387-402. doi: 10.3904/kjim.2013.28.4.387. Epub 2013 Jul 1.
3
Clinical Application of Bone Marrow Mesenchymal Stem/Stromal Cells to Repair Skeletal Tissue.
Int J Mol Sci. 2020 Dec 21;21(24):9759. doi: 10.3390/ijms21249759.
4
Characterization and therapeutic applications of mesenchymal stem cells for regenerative medicine.
Tissue Cell. 2020 Jun;64:101330. doi: 10.1016/j.tice.2020.101330. Epub 2020 Jan 10.
5
Expansion and Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stromal Cells.
Methods Mol Biol. 2021;2221:15-28. doi: 10.1007/978-1-0716-0989-7_2.
6
Mesenchymal Stem Cell Migration and Tissue Repair.
Cells. 2019 Jul 28;8(8):784. doi: 10.3390/cells8080784.
9
Mesenchymal Stem Cells for Regenerative Medicine.
Cells. 2019 Aug 13;8(8):886. doi: 10.3390/cells8080886.

引用本文的文献

1
Research advances in mesenchymal stem cells and related therapies for rotator cuff tendon-to-bone healing.
Front Bioeng Biotechnol. 2025 Aug 18;13:1647909. doi: 10.3389/fbioe.2025.1647909. eCollection 2025.
2
Impacts of stem cells from different sources on wound healing rate in diabetic foot ulcers: a systematic review and meta-analysis.
Front Genet. 2025 Jan 28;15:1541992. doi: 10.3389/fgene.2024.1541992. eCollection 2024.
6
Immunomodulatory differences between mesenchymal stem cells from different oral tissues.
Heliyon. 2023 Dec 13;10(1):e23317. doi: 10.1016/j.heliyon.2023.e23317. eCollection 2024 Jan 15.
8
Circulating Osteoprogenitor Cells Have a Mixed Immune and Mesenchymal Progenitor Function in Humans.
Stem Cells. 2023 Nov 5;41(11):1060-1075. doi: 10.1093/stmcls/sxad064.
10
Oral cavity-derived stem cells and preclinical models of jaw-bone defects for bone tissue engineering.
Stem Cell Res Ther. 2023 Mar 16;14(1):39. doi: 10.1186/s13287-023-03265-z.

本文引用的文献

2
An Innovative, Comprehensive Mapping and Multiscale Analysis of Registered Trials for Stem Cell-Based Regenerative Medicine.
Stem Cells Transl Med. 2016 Jun;5(6):826-35. doi: 10.5966/sctm.2015-0329. Epub 2016 Apr 13.
3
Using mesenchymal stem cells as a therapy for bone regeneration and repairing.
Biol Res. 2015 Nov 3;48:62. doi: 10.1186/s40659-015-0053-4.
4
Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Horm Metab Res. 2015 Sep;47(10):773-8. doi: 10.1055/s-0035-1555762. Epub 2015 Sep 11.
5
Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Stem Cells Transl Med. 2015 Jun;4(6):590-7. doi: 10.5966/sctm.2014-0212. Epub 2015 May 1.
7
Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles.
Curr Opin Organ Transplant. 2015 Feb;20(1):72-8. doi: 10.1097/MOT.0000000000000158.
8
Optimized cell survival and seeding efficiency for craniofacial tissue engineering using clinical stem cell therapy.
Stem Cells Transl Med. 2014 Dec;3(12):1495-503. doi: 10.5966/sctm.2014-0039. Epub 2014 Nov 5.
9
The relative merits of cord blood as a cell source for autologous T regulatory cell therapy in type 1 diabetes.
Horm Metab Res. 2015 Jan;47(1):48-55. doi: 10.1055/s-0034-1394372. Epub 2014 Nov 5.
10
Humanized mouse models for type 1 diabetes including pancreatic islet transplantation.
Horm Metab Res. 2015 Jan;47(1):43-7. doi: 10.1055/s-0034-1390446. Epub 2014 Nov 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验